| Name | Title | Contact Details |
|---|
McLaren Racing was founded by racing driver Bruce McLaren in 1963. The team entered its first Formula 1 race in 1966. McLaren has since won 21 Formula 1 world championships, 189 Formula 1 Grands Prix, the Indianapolis 500 three times, and the Le Mans 24 Hours at its first attempt. McLaren Racing competes across six racing series. The team competes in the FIA Formula 1 World Championship with McLaren F1 drivers Lando Norris and Oscar Piastri, the NTT INDYCAR SERIES with Arrow McLaren drivers Pato OWard, Alexander Rossi and Nolan Siegel, the ABB FIA Formula E World Championship with NEOM McLaren Formula E Team drivers Sam Bird and Taylor Barnard, the Extreme E Championship with NEOM McLaren Extreme E Team drivers Cristina Gutiérrez and Mattias Ekström, and F1 Academy with ART Grand Prix and Driver Development programme member Bianca Bustamante. The team also competes in the F1 Sim Racing Championship as McLaren Shadow, having won the 2022 Constructors and Drivers Championships. McLaren is a champion for sustainability in the sport and a signatory to the UN Sports for Climate Action Commitment. It is committed to achieving net zero by 2040 and fostering a diverse and inclusive culture in the motorsport industry.
Unlocking Your Businesss Full Potential with AI At AI Nomics, were driven by the vision to revolutionize your business approach. Our mission is to empower you to take on your operations with AI by your side, helping you overcome challenges and achieve your goals faster than ever before. How We Transform Your Business: The AI Nomics Approach Were here to make sure you spend more time doing what you love and less time on the mundane. Our framework is designed for smooth AI integration to address your needs and accelerate your success: The 4 As of AI Integration: 1. Analyze: We identify areas where AI can have the greatest impact and help define your goals. 2. Automate: We pinpoint repetitive tasks suitable for automation to save you time. 3. Augment: We find opportunities where AI can enhance your efficiency in crucial tasks. 4. Activate: We seamlessly integrate and activate tailored AI solutions into your operations. The AI Business Suite: Tools Tailored for Transformation Our AI Business Suite offers a range of smart tools designed for seamless integration, allowing you to harness the full benefits of AI effortlessly: • CustomerCare AI: Transform your customer interactions with an AI that handles queries and personalizes responses around the clock. • SalesBooster: Equip your site with a virtual sales expert that turns visitors into sales, any time of day. • LeadNova: Enhance your outreach with AI that personalizes communication and efficiently converts prospects into loyal customers. Get Started Now on your AI transformation journey: Claim your free AI consultation in our bio!
GO ARMY I BEAT NAVY! The U.S. Military Academy competes as ARMY WEST POINT in a broad range of NCAA D-1 and D-2 sports. At West Point, its all fun and games for ARMY fans, but every cadet on the field or court understands that competition through their sport is a critical component for developing their leadership and teamwork skills, and especially for building personal bonds. West Points competitive sports programs support the Army values of loyalty, duty, respect, selfless service, honor, integrity, and personal courage. It is designed to teach these values in an athletic setting. The nature of competitive sports provides opportunities that are difficult to replicate in the conventional classroom, in other extracurricular activities, or in military field training.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.